Tcr2 therapeutics inc. (TCRR)
Balance Sheet / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18
Assets
Current assets
Cash and cash equivalents

31,093

65,296

49,317

40,980

46,405

47,674

Investments

95,023

92,828

111,688

128,646

115,251

75,493

Prepaid expenses and other current assets

6,841

5,061

5,612

6,051

3,929

2,326

Total current assets

132,957

163,185

166,617

175,677

165,585

125,493

Property and equipment, net

5,220

4,926

4,463

3,172

1,936

1,638

Investments, non-current

14,540

0

8,014

11,121

30,048

-

Restricted cash

417

417

417

290

290

290

Deferred offering costs

170

0

0

0

0

2,012

Total assets

153,304

168,528

179,511

190,260

197,859

129,433

Liabilities, redeemable convertible preferred stock and stockholders’ equity (deficit)
Accounts payable

3,179

2,483

3,621

4,044

2,830

2,663

Accrued expenses and other current liabilities

2,950

5,050

4,262

3,116

2,527

2,802

Total current liabilities

6,129

7,533

7,883

7,160

5,357

5,465

Other liabilities

583

546

474

464

455

434

Total liabilities

6,712

8,079

8,357

7,624

5,812

5,899

Redeemable convertible preferred stock

-

-

0

-

-

209,230

Stockholders’ equity (deficit)
Preferred stock, $0.0001 par value. 10,000,000 shares, no shares issued or outstanding at March 31, 2020 and December 31, 2019, respectively.

0

0

0

0

0

0

Common stock, $0.0001 par value; 150,000,000 authorized; 24,075,906 and 24,050,936 shares issued; 24,056,469 and 23,981,109 shares outstanding at March 31, 2020 and December 31, 2019, respectively.

2

2

2

2

2

-

Additional paid-in capital

345,149

342,896

340,686

-

-

0

Additional paid-in capital

-

-

-

338,380

336,939

-

Accumulated other comprehensive income (loss)

-462

142

230

212

1

-106

Accumulated deficit

-198,097

-182,591

-169,764

-155,958

-144,895

-85,590

Total stockholders’ equity (deficit)

146,592

160,449

171,154

182,636

192,047

-85,696

Total liabilities, redeemable convertible preferred stock, and stockholders’ equity (deficit)

153,304

168,528

179,511

190,260

197,859

129,433

Series A redeemable convertible preferred stock
Redeemable convertible preferred stock

-

-

0

0

0

72,980

Series B redeemable convertible preferred stock
Redeemable convertible preferred stock

-

-

0

0

0

136,250